TD Cowen Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • TD Cowen raised its price target on Kiniksa Pharmaceuticals to $115 from $100 and maintained a Buy rating, implying about 21% upside from the prior close.
  • Analyst sentiment is broadly positive: eight analysts rate the stock Buy and two rate it Hold, with a consensus target of $102.38.
  • Kiniksa beat quarterly expectations, reporting EPS of $0.56 versus $0.37 forecast and revenue of $285.97 million versus $260.66 million expected.
  • Interested in Kiniksa Pharmaceuticals International? Here are five stocks we like better.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) had its target price increased by stock analysts at TD Cowen from $100.00 to $115.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a "buy" rating on the stock. TD Cowen's price target would indicate a potential upside of 21.19% from the stock's previous close.

Several other research analysts have also recently weighed in on the stock. Citigroup upped their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, October 28th. Canaccord Genuity Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a research report on Wednesday, July 29th. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 30th. Finally, Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 28th. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Moderate Buy" and a consensus target price of $102.38.

Check Out Our Latest Analysis on KNSA

Kiniksa Pharmaceuticals International Trading Up 0.7%

NASDAQ:KNSA opened at $94.89 on Tuesday. Kiniksa Pharmaceuticals International has a 1 year low of $37.02 and a 1 year high of $99.31. The stock has a market cap of $7.46 billion, a price-to-earnings ratio of 72.85 and a beta of 0.07. The stock has a 50-day moving average price of $82.50 and a two-hundred day moving average price of $62.96.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analysts' expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post 1.30 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CEO Sanj K. Patel sold 151,300 shares of the company's stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total value of $14,329,623.00. Following the transaction, the chief executive officer owned 774,500 shares in the company, valued at approximately $73,352,895. This represents a 16.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 18,413 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $93.39, for a total transaction of $1,719,590.07. Following the completion of the transaction, the insider directly owned 69,922 shares in the company, valued at approximately $6,530,015.58. This represents a 20.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 842,302 shares of company stock worth $78,587,130 in the last quarter. 51.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Several hedge funds have recently bought and sold shares of the stock. Allworth Financial LP grew its stake in shares of Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company's stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Curry Webb Wealth Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the third quarter worth approximately $29,000. Global Retirement Partners LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 315.5% during the third quarter. Global Retirement Partners LLC now owns 428 shares of the company's stock worth $32,000 after purchasing an additional 325 shares during the period. KBC Group NV bought a new position in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $34,000. Finally, Nykredit A S acquired a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $34,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

(Get Free Report)

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa's marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

Recommended Stories

Analyst Recommendations for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Kiniksa Pharmaceuticals International Right Now?

Before you consider Kiniksa Pharmaceuticals International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kiniksa Pharmaceuticals International wasn't on the list.

While Kiniksa Pharmaceuticals International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines